References
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39. https://doi.org/10.1016/S0140-6736(96)09457-3
- Chae SC. Antiplatelet agents in high-risk patients with coronary artery disease. Korean Circ J 2004;34:23-7.
- Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared ticlopidine in combination with as-pirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-9. https://doi.org/10.1161/01.CIR.102.6.624
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. https://doi.org/10.1056/NEJMoa010746
- Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomiz-ed and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
- Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. https://doi.org/10.1056/NEJM199604253341702
- Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71. https://doi.org/10.1161/01.CIR.103.15.1967
- Schomig A, Mehilli J, Holle H, et al. Statin treatment following coronary stenting and one-year survival. J Am Coll Cardiol 2002;40:854-61. https://doi.org/10.1016/S0735-1097(02)02053-3
- Baek JH, Choe KH, Jun JE, et al. Multicenter clinical trial of atorvastatin in patients with hypercholesterolemia. Korean Circ J 2001;31:434-41.
- Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus Atorvastatin 20 mg. Korean Circ J 2007;37:154-60. https://doi.org/10.4070/kcj.2007.37.4.154
- Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-32. https://doi.org/10.1016/0006-2952(92)90445-O
- Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-7.
- Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological ac-tivity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6.
- Clarke TA, Wakell LA. The metabolism of clopidogrel is catalyzed by human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9. https://doi.org/10.1124/dmd.31.1.53
- Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the abi-lity of clopidogrel to inhibit platelet aggregation: a new drug-drug in-teraction. Circulation 2003;107:32-7. https://doi.org/10.1161/01.CIR.0000047060.60595.CC
- Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003;24:1744-9. https://doi.org/10.1016/S0195-668X(03)00442-1
- Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomiz-ed, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4. https://doi.org/10.1161/01.CIR.0000088780.57432.43
- Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92:285-8. https://doi.org/10.1016/S0002-9149(03)00626-X
- Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8. https://doi.org/10.1161/01.CIR.0000124581.18191.15
- Serebruany VL, Midei MG, Malinin Al, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7. https://doi.org/10.1001/archinte.164.18.2051
- Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clo-pidogrel-CYP3A4 statin interaction in patients with acute coronary syn-drome. Heart 2005;91:23-6. https://doi.org/10.1136/hrt.2004.035014
- Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29:1635-43. https://doi.org/10.1093/eurheartj/ehn212
- Hong SJ, Park JY, Kim KA, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. Circ J 2009;73:1111-8. https://doi.org/10.1253/circj.CJ-08-1120
- World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed 2 December 2008).
- Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. https://doi.org/10.1161/01.CIR.101.2.207
- Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91. https://doi.org/10.3758/BF03193146
- Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphism of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-9. https://doi.org/10.1253/circj.72.1165
- Lee KH, Lee SW, Lee JW, et al. The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow P2Y21 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J 2009; 39:512-8. https://doi.org/10.4070/kcj.2009.39.12.512
- Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005;35:476-81. https://doi.org/10.1111/j.1365-2362.2005.01522.x
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
- Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequi-valence Studies. New York: Marcel Dekker;1999.
- Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. New York: Marcel Dekker;2003.
Cited by
- A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: A magnetic resonance imaging study vol.163, pp.3, 2011, https://doi.org/10.1016/j.ahj.2011.12.007
- Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease : Is There any Place for Novel Agents? vol.65, pp.6, 2011, https://doi.org/10.1177/0003319713499609
- Thromboelastography evaluation of low response to clopidogrel in patients with acute coronary syndrome vol.12, pp.1, 2011, https://doi.org/10.1016/j.ijge.2017.07.007